The Number of Regulatory T Cells Correlates with Hemodynamic Improvement in Patients with Inflammatory Dilated Cardiomyopathy After Immunoadsorption Therapy

• Published in: Scandinavian journal of immunology Vol. 77; no. 1; pp. 54 - 61
• Main Authors: Bulut, D., Creutzenberg, G., Mügge, A.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.01.2013
• Subjects: Adsorption; Adult; Autoantibodies; Autoantibodies - metabolism; Blood levels; C-reactive protein; C-Reactive Protein - metabolism; Cardiomyopathy; Cardiomyopathy, Dilated - immunology; Cardiomyopathy, Dilated - therapy; Dilated cardiomyopathy; Echocardiography; Female; Flow cytometry; Heart; Heart diseases; Heart Function Tests; Heart Ventricles - immunology; Helper cells; Hemodynamics; Hemodynamics - immunology; Humans; Immunoregulation; Immunosorbent Techniques; Immunotherapy - methods; Inflammation; Leukocytes; Lymphocyte Count; Lymphocytes T; Male; Middle Aged; Muscle contraction; Myocardial Contraction - immunology; Prospective Studies; T-Lymphocyte Subsets - immunology; T-Lymphocytes, Regulatory - immunology; Ventricle
• ISSN: 0300-9475; 1365-3083
• DOI: 10.1111/sji.12000

Inflammatory DCM (iDCM) may be related to autoimmune processes. An immunoadsorption (IA) has been reported to improve cardiac hemodynamics. The benefit of IA is probably related to the removal of autoantibodies. A recent study suggests additional effects of IA on the T cell–mediated immune reactions, especially on regulatory T cells (Tregs). In this prospective study, the correlation between the level of Tregs and improvement of myocardial contractility in response to IA in patients with iDCM was investigated. Patients (n = 18) with iDCM, reduced left ventricular (LV) ejection fraction (<35%), were enrolled for IA. Before and 6 months after IA, LV systolic function was assessed by echocardiography, and blood levels of Tregs were quantified by FACS analysis. Patients (n = 12) with chronic ischaemic heart failure and comparable reduced LV‐EF served as controls. IA improved LV‐EF in 12 of 18 patients at 6‐month follow‐up. These patients were classified as ‘IA responder’. In 6 patients, LV‐EF remained unchanged. At baseline, IA responder and non‐responder subgroups showed similar values for C‐reactive protein, white blood cells, lymphocytes and T helper cells, but they differ for the number of circulating Tregs (responder: 2.32 ± 1.38% versus non‐responder: 4.86 ± 0.28%; P < 0.01). Tregs increased significantly in the IA responders, but remained unchanged in the IA non‐responders. In patients with ischaemic cardiomyopathy, none of these values changed over time. A low level of Tregs in patients with chronic iDCM may characterize a subset of patients who do best respond to IA therapy.